Effects of CPAP on nitrate and norepinephrine levels in severe and mild-moderate sleep apnea

BMC Pulm Med. 2013 Mar 13:13:13. doi: 10.1186/1471-2466-13-13.

Abstract

Background: Reduced plasma nitrate (NO(x)) levels and increased urinary norepinephrine (U-NE) levels have been described in severe obstructive sleep apnea (OSA), and are reverted by continuous positive airway pressure (CPAP). The effect of CPAP on these biomarkers in mild-moderate OSA is not well understood. The aim of this study was to compare NO(x) and U-NE levels and blood pressure (BP) between male patients with mild-moderate and severe OSA and determine the impact of 1 month of CPAP therapy on these parameters.

Methods: We undertook a prospective study of 67 consecutive OSA patients (36 mild-moderate, 31 severe). Measurements of plasma NO(x) at 11 pm, 4 am and 7 am, 24-h U-NE and ambulatory BP were obtained at baseline and after 1 month of CPAP.

Results: At baseline, NO(x) levels showed a significant decrease during the night in both groups (p < 0.001). U-NE level and BP were significantly higher in the severe OSA group. After 1 month of CPAP, there was a significant increase in NO(x) levels and a reduction in U-NE level and BP only in patients with severe OSA.

Conclusions: One month of CPAP results in significant improvements in NO(x) levels, 24-h U-NE level and BP in patients with severe OSA, but not in patients with mild-moderate OSA.

Trial registration: ClinicalTrials.gov: NCT01769807.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Biomarkers / urine
  • Blood Pressure Monitoring, Ambulatory
  • Continuous Positive Airway Pressure / methods*
  • Humans
  • Male
  • Middle Aged
  • Nitrates / blood*
  • Norepinephrine / urine*
  • Oxygen / blood
  • Polysomnography
  • Prospective Studies
  • Severity of Illness Index
  • Sleep Apnea Syndromes / metabolism*
  • Sleep Apnea Syndromes / therapy*
  • Treatment Outcome

Substances

  • Biomarkers
  • Nitrates
  • Oxygen
  • Norepinephrine

Associated data

  • ClinicalTrials.gov/NCT01769807